Kailix Advisors LLC Acquires New Stake in Albemarle Corporation $ALB

Kailix Advisors LLC bought a new position in Albemarle Corporation (NYSE:ALB) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 144,500 shares of the specialty chemicals company’s stock, valued at approximately $11,716,000. Albemarle accounts for about 15.9% of Kailix Advisors LLC’s investment portfolio, making the stock its 2nd largest holding. Kailix Advisors LLC owned about 0.12% of Albemarle as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cromwell Holdings LLC grew its holdings in shares of Albemarle by 36.8% in the third quarter. Cromwell Holdings LLC now owns 413 shares of the specialty chemicals company’s stock worth $34,000 after purchasing an additional 111 shares during the last quarter. Money Concepts Capital Corp grew its stake in Albemarle by 1.2% in the 3rd quarter. Money Concepts Capital Corp now owns 10,160 shares of the specialty chemicals company’s stock worth $824,000 after acquiring an additional 116 shares in the last quarter. QRG Capital Management Inc. increased its position in shares of Albemarle by 3.3% during the third quarter. QRG Capital Management Inc. now owns 3,810 shares of the specialty chemicals company’s stock worth $309,000 after acquiring an additional 122 shares during the period. Allspring Global Investments Holdings LLC grew its stake in Albemarle by 2.1% in the third quarter. Allspring Global Investments Holdings LLC now owns 6,662 shares of the specialty chemicals company’s stock worth $563,000 after purchasing an additional 137 shares in the last quarter. Finally, SlateStone Wealth LLC increased its holdings in Albemarle by 2.8% during the 2nd quarter. SlateStone Wealth LLC now owns 5,415 shares of the specialty chemicals company’s stock worth $339,000 after purchasing an additional 145 shares during the period. 92.87% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Stephens reiterated an “outperform” rating on shares of Albemarle in a report on Friday, December 19th. Deutsche Bank Aktiengesellschaft raised shares of Albemarle from a “hold” rating to a “buy” rating and upped their price objective for the stock from $125.00 to $185.00 in a research note on Monday, January 12th. Jefferies Financial Group raised their target price on shares of Albemarle from $210.00 to $230.00 and gave the company a “buy” rating in a research report on Wednesday, January 28th. JPMorgan Chase & Co. lowered their price target on shares of Albemarle from $195.00 to $145.00 and set a “neutral” rating for the company in a research report on Friday. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Albemarle in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $162.72.

Albemarle Stock Up 4.7%

NYSE:ALB opened at $166.42 on Friday. The company’s 50-day simple moving average is $158.16 and its 200-day simple moving average is $115.03. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.51 and a current ratio of 2.23. Albemarle Corporation has a fifty-two week low of $49.43 and a fifty-two week high of $195.68. The stock has a market capitalization of $19.61 billion, a P/E ratio of -28.94, a P/E/G ratio of 2.29 and a beta of 1.44.

Albemarle (NYSE:ALB) last posted its earnings results on Wednesday, February 11th. The specialty chemicals company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.13). Albemarle had a negative net margin of 10.74% and a positive return on equity of 0.41%. The firm had revenue of $1.43 billion for the quarter, compared to analysts’ expectations of $1.34 billion. During the same period in the previous year, the company earned ($1.09) EPS. The company’s revenue was up 15.9% on a year-over-year basis. On average, equities analysts anticipate that Albemarle Corporation will post -0.04 earnings per share for the current fiscal year.

Key Headlines Impacting Albemarle

Here are the key news stories impacting Albemarle this week:

• Positive Sentiment: Revenue beat and strong Energy Storage demand — Q4 revenue topped estimates with ~16% y/y growth driven by Energy Storage volumes and pricing, a primary reason bulls cite for upside in ALB. ALB Q4 Earnings Miss, Revenues Beat on Higher Volumes & Pricing
• Positive Sentiment: Raised FY‑2026 revenue guidance — management issued a FY‑26 revenue range (~$5.7B–$6.0B) above consensus, giving investors a forward revenue anchor amid lithium price swings. Is Albemarle Setting Up for a Lithium-Fueled Rebound?
• Positive Sentiment: Analyst upside moves — Morgan Stanley and Mizuho raised price targets (to $170 and $185 respectively), signaling some sell‑side conviction on medium-term fundamentals. Morgan Stanley raises price target on Albemarle Mizuho raises price target on Albemarle
• Positive Sentiment: U.S. production support and grants — company commentary and coverage highlight DOE support (Kings Mountain reactivation) and domestic production steps that improve supply‑chain optionality. Is Albemarle Setting Up for a Lithium-Fueled Rebound?
• Neutral Sentiment: Earnings call tone — management emphasized cash strength, disciplined capacity management and flexibility across cycles; those points reduce tail‑risk but leave near‑term volatility intact. Albemarle Earnings Call: Cash Strength Amid Lithium Cycles Albemarle Q4 2025 Earnings Call Transcript
• Positive Sentiment: Potential policy tailwinds — the House passed H.R.3617 (Securing America’s Critical Minerals Supply Act), which could support domestic critical‑minerals investment over time. Congress Vote: The House has passed H.R.3617
• Negative Sentiment: EPS miss and wider loss — Albemarle reported a larger-than-expected Q4 loss (missed EPS estimates), a headline that keeps short-term sellers active. ALB Q4 Earnings Miss, Revenues Beat on Higher Volumes & Pricing
• Negative Sentiment: Not all analysts are bullish — JPMorgan cut its price target to $145 (neutral), a headline that can cap near‑term upside. JPMorgan adjusts price target on Albemarle to $145 from $195
• Negative Sentiment: Macro and lithium price volatility — broader market rate/volatility concerns and swings in lithium prices mean ALB can move sharply both ways; expect continued choppy trading. MarketBeat Week in Review

About Albemarle

Albemarle Corporation is a leading global specialty chemicals company primarily engaged in the production and distribution of lithium, bromine, and catalysts. Its lithium segment supplies key components used in rechargeable batteries for electric vehicles, portable electronics, and grid storage systems. The company’s bromine specialty products serve a wide range of industries, including oil and gas drilling fluids, fire safety solutions, and water treatment. In its catalysts division, Albemarle provides products for petroleum refining, chemical processing and emissions control.

Founded in 1994 as a spin-off from Ethyl Corporation, Albemarle has grown through strategic acquisitions and capacity expansions to become one of the world’s foremost chemical producers.